menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Supriya Lifescience expands global footprint with Esketamine HCL

    PRESS RELEASE

    J&J Showcases Neuropsychiatry Portfolio At Psych Congress

    PR NEWSWIRE

    J&J seeks expanded approval for antidepressant Spravato

    PRESS RELEASE

    OptiMed Introduces New Service For Treatment-Resistant Depression

    ACCESSWIRE

    Johnson & Johnson 1Q Results

    CONTRACT PHARMA

    Data Suggests SPRAVATO is More Tolerable and Effective Compared to Quetiapine XR

    GLOBENEWSWIRE

    FDA Confirms Paragraph IV Patent Litigation for Esketamine Hydrochloride

    FDA

    China Approves Sales of Janssen’s Antidepressant

    YICAIGLOBAL

    New Data from the Phase 3b ESCAPE-TRD Study Show that Participants Receiving SPRAVATO Achieved Higher Response and Remission Rates, Increasing Over Time, Compared to those Receiving Quetiapine Extended-Release

    GLOBENEWSWIRE

    Nasal spray could help prevent depression relapse

    EUROPEANPHARMACEUTICALREVIEW

    Janssen’s Phase IIIb major depressive disorder trial meets primary endpoint

    CLINICALTRIALSARENA

    J&J builds case for Spravato in tough-to-treat depression

    FIERCEPHARMA

    SPRAVATO data from the phase 3b ESCAPE-TRD study demonstrate superior efficacy

    BUSINESSWIRE

    Stigma in drug research holding back new therapies

    ECONOMIC TIMES

    NICE`s rebuff of J&J depression nasal spray under scrutiny

    FIERCEPHARMA

    Janssen`s Chemical Spravato (Esketamine HCl) Receives Approval in the U.S.

    FDA

    NLS Initiates Ph2 Trial for Quilience in Narcolepsy

    ACESSWIRE

    PharmaTher Provides Research and Development Update and Milestones for 2021

    GLOBENEWSWIRE

    AJP Publishes International Ketamine and Esketamine Treatment Guidance

    PRNEWSWIRE

    Janssen`s esketamine nasal spray gets Europe approval for new indication

    PHARMAFILE

    Janssen Receives Positive CHMP Opinion for SPRAVATO®

    BUSINESSWIRE

    Janssen Receives Positive CHMP Opinion for SPRAVATO®?

    BUSINESSWIRE

    NICE knocks back Janssens Spravato nasal spray for the second time in treatment

    PHARMAFILE

    Champignon to Begin Offering Esketamine Treatment for Adults With MSD

    GLOBENEWSWIRE

    Johnson & Johnson Spray Approved for Treating Suicidal People

    BNNBLOOMBERG

    (n)SPRAVATO® (esketamine)* Nasal Spray is Available for Canadian Patients

    MARKETS

    J&J`s depression spray Spravato fails cost-effectiveness review

    FIERCE PHARMA

    J&J gets EU approval for depression nasal spray Spravato

    PM LIVE

    Janssen-Cilag International Spravato (esketamine) Receives Approval In Europe

    EMA

    Janssen Receives Positive CHMP Opinion for Spravato

    PRESS RELEASE

    Janssen Submits Supplemental NDA to U.S. FDA for SPRAVATO® (esketamine)

    PR NEWSWIRE

    J&J scores Spravato trial win in high-risk depression

    FIERCE PHARMA

    Get as much Spravato as you can, Trump orders VA while suggesting J&J

    ENDPTS

    J&J depression drug Spravato gets half-hearted backing from VA doctors

    FIERCE PHARMA

    Cost-effectiveness watchdogs skewer J&J`s depression spray Spravato

    FIERCE PHARMA

    FDA Overlooked Red Flags In Drugmaker’s Testing of New Depression Medicine

    KHN

    Stung by critics, J&J says antidepressant Spravato saves money

    PMLIVE

    New data highlights value of Janssen’s Spravato

    PHARMA TIMES

    Cost watchdogs take issue with J&J`s Spravato price

    FIERCE PHARMA

    Esketamine and psychedelics will require restructuring mental health care visits

    STATNEWS

    The FDA just approved this groundbreaking antidepressant nasal spray

    SLASHGEAR

    Addiction specialist expresses concern after FDA approves esketamine

    IN- PHARMATECHNOLOGIST

    J&J’s Spravato breaks depression drought at FDA

    PMLIVE

    So you just got a BTD for your top drug? Don’t be surprised

    ENDPTS

    Johnson & Johnson`s nasal spray for depression wins FDA panel backing

    REUTERS

    Depression Therapy With Party-Drug Roots Faces FDA Panel Review

    BLOOMBERG

    J&J’s Esketamine for Depression Faces an FDA Panel Next Week

    BIOSPACE

    Janssen Submits EMA Application for Esketamine Nasal Spray

    BUSINESSWIRE

    Janssen files nasal spray for depression

    PHARMA TIMES

    Janssen Announces Results of Esketamine Nasal Spray

    PR NEWSWIRE

    J&J racks up fresh +ve pivotal data for esketamine amidst safety concerns

    ENDPTS

    Aspen Moves Production to New $79 Million South Africa Plant

    BLOOMBERG

    J&J preps for esketamine filing in resistant depression, despite a missed trial

    FIERCE BIOTECH

    Nasal spray of party drug shows promise as fast-acting antidepressant

    WASHINGTONPOST

    0-for-3 in PhIII: Auris’ late-stage changeup fails to save tinnitus drug

    ENDPTS

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.